These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 38574776)
1. Sustained clinical benefit of malaria chemoprevention with sulfadoxine-pyrimethamine (SP) in pregnant women in a region with high SP resistance markers. Matambisso G; Brokhattingen N; Maculuve S; Cístero P; Mbeve H; Escoda A; Bambo G; Cuna B; Melembe C; Ndimande N; Tetteh KKA; Drakeley C; Gamain B; Chitnis C; Chauhan V; Quintó L; Macete E; Mayor A J Infect; 2024 May; 88(5):106144. PubMed ID: 38574776 [TBL] [Abstract][Full Text] [Related]
2. Predictors for the uptake of optimal doses of sulfadoxine-pyrimethamine for intermittent preventive treatment of malaria during pregnancy in Tanzania: further analysis of the data of the 2015-2016 Tanzania demographic and health survey and malaria indicator survey. Mushi V; Mbotwa CH; Zacharia A; Ambrose T; Moshi FV Malar J; 2021 Feb; 20(1):75. PubMed ID: 33549094 [TBL] [Abstract][Full Text] [Related]
3. Effect of Plasmodium falciparum sulfadoxine-pyrimethamine resistance on the effectiveness of intermittent preventive therapy for malaria in pregnancy in Africa: a systematic review and meta-analysis. van Eijk AM; Larsen DA; Kayentao K; Koshy G; Slaughter DEC; Roper C; Okell LC; Desai M; Gutman J; Khairallah C; Rogerson SJ; Hopkins Sibley C; Meshnick SR; Taylor SM; Ter Kuile FO Lancet Infect Dis; 2019 May; 19(5):546-556. PubMed ID: 30922818 [TBL] [Abstract][Full Text] [Related]
4. Sulfadoxine-pyrimethamine parasitological efficacy against Plasmodium falciparum among pregnant women and molecular markers of resistance in Zambia: an observational cohort study. Chaponda EB; Mharakurwa S; Michelo C; Bruce J; Chandramoha D; Matthew Chico R Malar J; 2021 Jan; 20(1):61. PubMed ID: 33482823 [TBL] [Abstract][Full Text] [Related]
5. Decline of placental malaria in southern Ghana after the implementation of intermittent preventive treatment in pregnancy. Hommerich L; von Oertzen C; Bedu-Addo G; Holmberg V; Acquah PA; Eggelte TA; Bienzle U; Mockenhaupt FP Malar J; 2007 Nov; 6():144. PubMed ID: 17996048 [TBL] [Abstract][Full Text] [Related]
6. Intermittent preventive treatment in pregnancy with sulfadoxine-pyrimethamine and parasite resistance: cross-sectional surveys from antenatal care visit and delivery in rural Ghana. Mama A; Ahiabor C; Tornyigah B; Frempong NA; Kusi KA; Adu B; Courtin D; Houzé S; Deloron P; Ofori MF; Anang AK; Ariey F; Ndam NT Malar J; 2022 Mar; 21(1):107. PubMed ID: 35346205 [TBL] [Abstract][Full Text] [Related]
7. Increase in the prevalence of mutations associated with sulfadoxine-pyrimethamine resistance in Plasmodium falciparum isolates collected from early to late pregnancy in Nanoro, Burkina Faso. Ruizendaal E; Tahita MC; Geskus RB; Versteeg I; Scott S; d'Alessandro U; Lompo P; Derra K; Traore-Coulibaly M; de Jong MD; Schallig HDFH; Tinto H; Mens PF Malar J; 2017 Apr; 16(1):179. PubMed ID: 28454537 [TBL] [Abstract][Full Text] [Related]
8. Intermittent screening and treatment with artemether-lumefantrine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in pregnancy: a facility-based, open-label, non-inferiority trial in Nigeria. Esu E; Berens-Riha N; Pritsch M; Nwachuku N; Loescher T; Meremikwu M Malar J; 2018 Jul; 17(1):251. PubMed ID: 29976228 [TBL] [Abstract][Full Text] [Related]
9. Safety and toxicity of sulfadoxine/pyrimethamine: implications for malaria prevention in pregnancy using intermittent preventive treatment. Peters PJ; Thigpen MC; Parise ME; Newman RD Drug Saf; 2007; 30(6):481-501. PubMed ID: 17536875 [TBL] [Abstract][Full Text] [Related]
10. Uptake of intermittent preventive treatment and pregnancy outcomes: health facilities and community surveys in Chókwè district, southern Mozambique. Arnaldo P; Rovira-Vallbona E; Langa JS; Salvador C; Guetens P; Chiheb D; Xavier B; Kestens L; Enosse SM; Rosanas-Urgell A Malar J; 2018 Mar; 17(1):109. PubMed ID: 29530044 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of sulphadoxine-pyrimethamine for intermittent preventive treatment of malaria in pregnancy, Mansa, Zambia. Tan KR; Katalenich BL; Mace KE; Nambozi M; Taylor SM; Meshnick SR; Wiegand RE; Chalwe V; Filler SJ; Kamuliwo M; Craig AS Malar J; 2014 Jun; 13():227. PubMed ID: 24909578 [TBL] [Abstract][Full Text] [Related]
12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
13. Interactions Between Antenatal Sulfadoxine-Pyrimethamine, Drug-Resistant Plasmodium falciparum Parasites, and Delivery Outcomes in Malawi. Taylor SM; Levitt B; Freedman B; Madanitsa M; Thwai KL; Kalilani-Phiri L; Khairallah C; Mwapasa V; Ter Kuile FO; Meshnick SR J Infect Dis; 2020 Jul; 222(4):661-669. PubMed ID: 32221555 [TBL] [Abstract][Full Text] [Related]
14. Estimated impact on birth weight of scaling up intermittent preventive treatment of malaria in pregnancy given sulphadoxine-pyrimethamine resistance in Africa: A mathematical model. Walker PG; Floyd J; Ter Kuile F; Cairns M PLoS Med; 2017 Feb; 14(2):e1002243. PubMed ID: 28245259 [TBL] [Abstract][Full Text] [Related]
15. Effectiveness of intermittent preventive treatment with sulfadoxine-pyrimethamine during pregnancy on maternal and birth outcomes in Machinga district, Malawi. Gutman J; Mwandama D; Wiegand RE; Ali D; Mathanga DP; Skarbinski J J Infect Dis; 2013 Sep; 208(6):907-16. PubMed ID: 23801600 [TBL] [Abstract][Full Text] [Related]
16. Antenatal receipt of sulfadoxine-pyrimethamine does not exacerbate pregnancy-associated malaria despite the expansion of drug-resistant Plasmodium falciparum: clinical outcomes from the QuEERPAM study. Taylor SM; Antonia AL; Chaluluka E; Mwapasa V; Feng G; Molyneux ME; ter Kuile FO; Meshnick SR; Rogerson SJ Clin Infect Dis; 2012 Jul; 55(1):42-50. PubMed ID: 22441649 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of sulphadoxine-pyrimethamine for intermittent preventive treatment of malaria in pregnancy: a retrospective birth outcomes study in Mansa, Zambia. Mace KE; Chalwe V; Katalenich BL; Nambozi M; Mubikayi L; Mulele CK; Wiegand RE; Filler SJ; Kamuliwo M; Craig AS; Tan KR Malar J; 2015 Feb; 14():69. PubMed ID: 25890159 [TBL] [Abstract][Full Text] [Related]
18. Decrease of microscopic Plasmodium falciparum infection prevalence during pregnancy following IPTp-SP implementation in urban cities of Gabon. Bouyou-Akotet MK; Mawili-Mboumba DP; Kendjo E; Moutandou Chiesa S; Tshibola Mbuyi ML; Tsoumbou-Bakana G; Zong J; Ambounda N; Kombila M Trans R Soc Trop Med Hyg; 2016 Jun; 110(6):333-42. PubMed ID: 27268713 [TBL] [Abstract][Full Text] [Related]
19. The prevalence of molecular markers of resistance to sulfadoxine-pyrimethamine among pregnant women at first antenatal clinic attendance and delivery in the forest-savannah area of Ghana. Dosoo DK; Bailey JA; Asante KP; Oppong FB; Niaré K; Opoku-Mensah J; Owusu-Agyei S; Greenwood B; Chandramohan D PLoS One; 2022; 17(8):e0271489. PubMed ID: 35939419 [TBL] [Abstract][Full Text] [Related]
20. Impact on pregnancy outcomes of intermittent preventive treatment with sulfadoxine-pyrimethamine in urban and peri-urban Papua New Guinea: a retrospective cohort study. Cellich P; Unger HW; Rogerson SJ; Mola GDL Malar J; 2024 Jul; 23(1):201. PubMed ID: 38970076 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]